BS_CXVJK2FY
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- overall_survival_months
- 34.75689881734559
- age_years
- 12.981
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.357
- ANGIOGENESIS+0.254
- HYPOXIA+0.249
- APOPTOSIS+0.241
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.239
- WNT_BETA_CATENIN_SIGNALING+0.225
- P53_PATHWAY+0.208
- CHOLESTEROL_HOMEOSTASIS+0.195
- UNFOLDED_PROTEIN_RESPONSE+0.193
- INTERFERON_ALPHA_RESPONSE+0.188
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.378
- E2F_TARGETS-0.333
- MYC_TARGETS_V1-0.320
- G2M_CHECKPOINT-0.272
- MYC_TARGETS_V2-0.271
- ALLOGRAFT_REJECTION-0.251
- HEME_METABOLISM-0.208
- PANCREAS_BETA_CELLS-0.203
- MITOTIC_SPINDLE-0.195
- FATTY_ACID_METABOLISM-0.186
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_CXVJK2FY | EPN | Supratentorial EPN | 0.868 |
| 2 | R365 | — | — | 0.742 |
| 3 | BS_5P3CZQV8 | Neurofibroma | — | 0.740 |
| 4 | 1af0bfa7-8beb-499f-a658-ed1dd9fdb701 | — | — | 0.734 |
| 5 | SRR2932823 | — | — | 0.730 |
| 6 | AUR-AER2-TTM3-A-1-1-R-A742-41 | — | D | 0.725 |
| 7 | SRR12475145 | — | — | 0.710 |
| 8 | SRR15069600 | — | — | 0.693 |
| 9 | 6b548699-9440-4acc-86b6-faeb367454a2 | — | — | 0.693 |
| 10 | TCGA-BA-6868-01B-12R-1915-07 | — | — | 0.688 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.357 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.254 | Remibrutinib | — uncovered |
| HYPOXIA | 0.249 | Idelalisib | — uncovered |
| APOPTOSIS | 0.241 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.239 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.225 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.208 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.195 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.193 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.188 | Inavolisib | — uncovered |
| COAGULATION | 0.163 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.158 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.134 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.127 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.115 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.096 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.081 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.079 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |